Pacific Biosciences of California, Inc.
PACB· Nasdaq
PACBPacific Biosciences of California, Inc.
Released Aug 5, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001299130-26-000122
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $39.01M | $39.77M | $36.01M | $47.57M |
| Net Income | -$44.74M | -$41.93M | -$173.32M | -$69.83M |
| EPS Diluted |
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR
| -$0.14 |
| -$0.14 |
| -$0.64 |
| -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
